Abciximab

In the US, Abciximab (abciximab systemic) is a member of the drug class glycoprotein platelet inhibitors and is used to treat High Risk Percutaneous Transluminal Angioplasty.

US matches:

• Abciximab


• Abciximab Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AC13

CAS registry number (Chemical Abstracts Service)

0143653-53-6

Chemical Formula

C2101-H3229-N55-O673-S15

Molecular Weight

47462

Therapeutic Categories

Biological response modifier, BRM

Antiplatelet agent, glycoprotein IIb/IIIa-receptor antagonist

Chemical Name

Immunoglobulin G (human-mouse monoclonal c7E3 clone p7E3VHhCy4 Fab fragment anti-human glyocoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VKhCK light chain

Foreign Names

• Abciximabum (Latin)
• Abciximab (German)
• Abciximab (French)
• Abciximab (Spanish)

Generic Names

• Abciximab (OS: USAN, BAN)
• c7E3 (IS)

Brand Names

• ReoPro
  Centocor, Austria; Centocor, Bulgaria; Centocor, Czech Republic; Centocor, Denmark; Centocor, Luxembourg; Centocor, Netherlands; Centocor, Norway; Centocor, Poland; Eli Lilly, Canada; Eli Lilly, United Kingdom; Eli Lilly, Netherlands; Eli Lilly, South Africa; Lilly, Australia; Lilly, Belgium; Lilly, Brazil; Lilly, Switzerland; Lilly, Chile; Lilly, Germany; Lilly, Spain; Lilly, Finland; Lilly, Greece; Lilly, Hong Kong; Lilly, Ireland; Lilly, Israel; Lilly, India; Lilly, Iceland; Lilly, Italy; Lilly, Sri Lanka; Lilly, Mexico; Lilly, Malaysia; Lilly, New Zealand; Lilly, Peru; Lilly, Romania; Lilly, Serbia; Lilly, Russian Federation; Lilly, Sweden; Lilly, Singapore; Lilly, Thailand; Lilly, Taiwan; Lilly, United States



• Réopro
  Lilly, France

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.